Article Contents ::
- 1 The Brand Name RADIOPAQUE Has Generic Salt :: Iohexol
- 2 RADIOPAQUE Is From Company Dabur Ph. Priced :: Rs. 1750
- 3 RADIOPAQUE have Iohexol is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name RADIOPAQUE Has Generic Salt :: Iohexol
RADIOPAQUE Is From Company Dabur Ph. Priced :: Rs. 1750
RADIOPAQUE have Iohexol is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
Iohexol | INJ | Rs. 1750 | 100ML |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 100ML |
RADIOPAQUE | Dabur Ph. | 300MG/ML | 100ML | Rs. 1750 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Dabur Ph. :: RADIOPAQUE | Iohexol | #N/A | #N/A |
Indications for Drugs ::
Radiographic contrast medium for diagnostic procedures
Drug Dose ::
Adult: Inj As iohexol soln containing 6-350 mg iodine/mL: Dose and strength used depends on the procedure and route of administration.
Contraindication ::
Procedure-specific. Intrathecal: Myelography in significant local or systemic infection where bacteremia is likely; concurrent use with corticosteroids; repeat myelography in the event of technical failure (risk of overdosage). Hysterosalpingography: During menstrual period or when menstrual flow in imminent; presence of infection; pregnancy, 6 mth after termination of pregnancy or 30 days after conization or curettage.
Drug Precautions ::
Asthma or a history of allergies (risk of anaphylactoid reactions is increased); compromised blood-brain barrier (severe neurotoxicity after intrathecal use); epilepsy and brain tumour (higher risk of convulsions); severe hepatic or renal impairment, diabetics with renal impairment, dehydration and others who may be at increased risk of renal failure; multiple myeloma (dehydration from use may cause precipitation of protein in the renal tubules, leading to anuria and fatal renal failure); severe hypertension; advanced cardiac disease; phaeochromocytoma; sickle-cell disease; hyperthyroidism; debilitated, severely ill, very old, or very young patients; occlusive vascular disease. Special care to ensure that 140 and 350 mg iodine/ml solutions are not given intrathecally. Adequate resuscitative facilities should be available when radiographic procedures are undertaken, and patients should be kept under observation for a suitable period after the procedure.
Drug Side Effects ::
Flushing or a sensation of heat; pain, extravasation, thrombophlebitis at the inj site; nausea, vomiting, headache, and dizziness; urticaria, pruritus, pallor, sweating, metallic taste, weakness, coughing, rhinitis, sneezing, lachrymation, visual disturbances; hypotension, tachycardia, bradycardia, transient ECG abnormalities, haemodynamic disturbances; dyspnoea, bronchospasm, angioedema, severe urticaria; convulsions, paraesthesia, paralysis; acute renal failure; thromboembolism, disseminated intravascular coagulation, thrombocytopenia; hyperthyroidism, thyroid storm thyrotoxicosis. Potentially Fatal: Profound hypotension, pulmonary oedema, respiratory arrest, ventricular fibrillation, circulatory failure, cardiac arrest, coma.
Pregnancy category ::
2
Drug Mode of Action ::
Allows for radiographic visualization through the opacification of vessels and anatomical structures in the path of flow of the contrast media.
Drug Interactions ::
0